PMID- 12800103
OWN - NLM
STAT- MEDLINE
DCOM- 20030711
LR  - 20190725
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 52
IP  - 6
DP  - 2003 Jun
TI  - Effect of thiazolidinediones on glucose and fatty acid metabolism in patients 
      with type 2 diabetes.
PG  - 753-9
AB  - The current study aimed to compare the effects of treatment (2 months) with 
      thiazolidinediones (TZDs) and placebo on glucose and fat metabolism in patients 
      with type 2 diabetes (T2DM) in a crossover design. Eight patients received 
      placebo (2 months) followed by TZD (2 months). Two-stage (1.5 and 6.0 pmol/kg 
      min) hyperinsulinemic-euglycemic clamps were performed in all 8 patients pre- and 
      post-placebo and post-TZD (post-placebo = pre-TZD). We determined rates of 
      glucose disappearance (G(Rd)), glycolysis (GLS), glycogen synthesis (GS) (all 
      with 3-(3)H glucose), carbohydrate (CHO) oxidation (indirect calorimetry), 
      endogenous glucose production (EGP), free fatty acid (FFA) release ((2)H(5) 
      glycerol), and oxidation (indirect calorimetry) and re-esterification, as well as 
      plasma adiponectin and leptin concentrations, and fat cell size and number 
      (determined in upper thigh biopsy samples). Placebo treatment had no effects on 
      any of the measured parameters. TZD treatment improved insulin-stimulated glucose 
      uptake (ISGU) from 17.1 to 26.4 micromol/kg min (P <.01) and insulin-stimulated 
      GS from 4.8 to 13.4 micromol/kg min (P < 0.03), potentiated insulin-induced 
      suppression of lipolysis from 4.3 to 2.3 micromol/kg min (P <.03) and FFA 
      re-esterification from 1.9 to 1.0 micromol/kg min (P <.02), increased plasma 
      adiponectin levels from 2.7 to 7.2 microg/mL (P <.05), and decreased plasma 
      leptin levels from 30.8 to 23.4 ng/mL (P <.02). In addition, TZD tended to 
      increase the number of small adipocytes (<50 microm) in subcutaneous adipose 
      tissue. We conclude that TZDs have multiple actions and that many, but perhaps 
      not all, can be accounted for by their action on adipose tissue.
FAU - Boden, Guenther
AU  - Boden G
AD  - Division of Endocrinology/Diabetes/Metabolism and the General Clinical Research 
      Center, Temple University School of Medicine, Philadelphia, PA 19140, USA.
FAU - Cheung, Peter
AU  - Cheung P
FAU - Mozzoli, Maria
AU  - Mozzoli M
FAU - Fried, Susan K
AU  - Fried SK
LA  - eng
GR  - R01-AA-10221/AA/NIAAA NIH HHS/United States
GR  - R01-DK58895/DK/NIDDK NIH HHS/United States
GR  - RR-349/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Adiponectin)
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Leptin)
RN  - 0 (Proteins)
RN  - 0 (Thiazoles)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adipocytes/pathology
MH  - Adiponectin
MH  - Blood Glucose/analysis
MH  - Cell Size
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/*metabolism/pathology
MH  - Esterification
MH  - Fatty Acids/*metabolism
MH  - Female
MH  - Glucose/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/blood
MH  - *Intercellular Signaling Peptides and Proteins
MH  - Leptin/blood
MH  - Lipolysis
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Proteins/analysis
MH  - Thiazoles/*therapeutic use
EDAT- 2003/06/12 05:00
MHDA- 2003/07/12 05:00
CRDT- 2003/06/12 05:00
PHST- 2003/06/12 05:00 [pubmed]
PHST- 2003/07/12 05:00 [medline]
PHST- 2003/06/12 05:00 [entrez]
AID - S0026049503000556 [pii]
AID - 10.1016/s0026-0495(03)00055-6 [doi]
PST - ppublish
SO  - Metabolism. 2003 Jun;52(6):753-9. doi: 10.1016/s0026-0495(03)00055-6.